Afamelanotide is a synthetic analogue of α-melanocyte-stimulating hormone whose established clinical role is increasing pain-free light exposure in adults with erythropoietic protoporphyria. The controlled-release prescription implant Scenesse stimulates protective skin pigment, helping address the severe light-triggered pain of this inherited disorder. Randomized trials and subsequent treatment registries support this disease-specific use. Earlier pigmentation experiments and a vitiligo add-on trial provide additional biological context with their own formulations, comparators and outcomes.
Overview
Afamelanotide contains thirteen amino-acid residues, with norleucine at the fourth position and D-phenylalanine at the seventh position relative to α-MSH. NDP-α-MSH and melanotan-I are historical research names for this modified peptide. Scenesse incorporates afamelanotide acetate into a bioresorbable polymer implant, which controls the release of the active compound. Scenesse prescribing information.
Molecular profile
- Form
- Afamelanotide acetate in Scenesse; neutral parent fields distinguished below Source
- Sequence
- Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 Source
- Length
- 13 amino-acid residues Source
- Molecular formula
- C78H111N21O19 (parent); acetate: C78H111N21O19·xC2H4O2, 3 ≤ x ≤ 4 Source
- Molecular mass
- 1646.85 Da (anhydrous free base) Source
Forms and derivatives
NDP-α-MSH / melanotan-I
Historical names for the α-MSH analogue carrying norleucine at position 4 and D-phenylalanine at position 7. The early route-comparison study used soluble research formulations.
Scenesse controlled-release implant
The approved product embeds afamelanotide acetate in a bioresorbable polymer that governs release after implantation.
The historical melanotan-I literature remains useful for following the molecule's development, especially the difference between a peptide's intrinsic behavior and the delivery system built around it. Ugwu's route-comparison study used soluble research formulations rather than the later clinical implant. Ugwu and colleagues (1997).
Uses and research areas
In EPP, accumulated protoporphyrin makes light exposure intensely painful. The condition involves heme synthesis, the pathway that produces the iron-containing component needed by several proteins. Light activates the accumulated photosensitive material in superficial tissues, producing painful phototoxic reactions that can strongly restrict everyday outdoor activity. The pivotal studies therefore measured pain-free time in sunlight and EPP-specific quality of life. Langendonk and colleagues (2015).
Scenesse's current US indication concerns adults with a history of EPP phototoxic reactions. Vitiligo research asks a different question: whether adding the implant to narrowband UV-B phototherapy improves repigmentation in selected adults with nonsegmental vitiligo. That combined strategy and its disease population define the inference from the trial. Current label; Lim and colleagues (2015).
Mechanism of action
Afamelanotide activates melanocortin receptors, predominantly MC1R on pigment-producing melanocytes. The resulting increase in eumelanin provides a protective pigment layer that can absorb and reduce the effects of light. This helps explain improved light tolerance in EPP even though the inherited heme-pathway defect remains. Patients' benefit depends on an altered response to exposure, with disease monitoring and light protection still part of care. Scenesse label; pivotal study.
Pigment production is a tissue response. Its time course can extend beyond the period when a particular plasma peptide concentration is detectable, which is why pigmentation or light tolerance cannot be used to infer the molecule's blood half-life. Ugwu's early study observed pigment changes after intravenous and subcutaneous exposure, while oral exposure produced no detectable circulating drug in the tested formulation. Ugwu and colleagues (1997).
Pharmacokinetics
The Scenesse label describes a single-implant study in twelve healthy adults. Median time to peak plasma concentration was 36 hours, and the apparent half-life was approximately 15 hours. Concentrations varied substantially between participants. These measurements include continuing release from the polymer implant, so they cannot be converted into a simple curve beginning with instant complete absorption. Current prescribing information, pharmacokinetics.
No concentration graph is supplied because the acquired label provides summary estimates without the original time-point observations. Ugwu's earlier three-man crossover study reports route-specific kinetics for soluble melanotan-I; those observations remain attached to its formulation rather than replacing the implant analysis. Original route-comparison report.
Research findings
Two controlled trials of pain-free light exposure
Langendonk and colleagues randomized 94 participants in the US and 74 in the European trial. Over six months, the US median accumulated pain-free sunlight exposure was 69.4 hours with afamelanotide versus 40.8 hours with placebo. Over nine months, the European medians were 6.0 versus 0.8 hours. The trials used different diary definitions and time windows, so the values describe separate outcomes rather than a directly comparable regional effect. Original pivotal report.
The European trial also found fewer phototoxic reactions with afamelanotide, while the US trial did not establish a difference in reaction counts. EPP-specific quality-of-life scores improved at several assessments, but the broader Dermatology Life Quality Index showed no change over time in either group. A questionnaire focused on EPP can capture changes in light-related pain and daily restrictions that a general skin-disease measure may miss. Langendonk and colleagues (2015).
Longer observations during specialist care
Biolcati and colleagues described 115 patients treated at centres in Rome and Zurich over follow-up extending up to eight years. EPP-specific quality-of-life scores rose from approximately 31% to 74% of the scale maximum and remained elevated during observed treatment. Reasons for stopping included pregnancy and financial restrictions as well as dissatisfaction, illustrating how access can influence a long-term cohort. Without a randomized concurrent comparator, the study estimates treatment experience and persistence rather than isolating every causal effect. Biolcati and colleagues (2015).
A German postauthorization analysis published in 2025 followed 200 treated registry participants enrolled during 2016–2021. At the cutoff, 182 continued treatment. Paired EPP quality-of-life assessments generally improved, with the participant subset varying across assessments. The enrollment period does not mean every participant received the same number of years of follow-up. Homey and colleagues (2025).
Vitiligo with phototherapy
Lim and colleagues randomized 55 adults to afamelanotide plus narrowband UV-B or narrowband UV-B alone. Participants had nonsegmental vitiligo and Fitzpatrick skin types III–VI. At day 168, average repigmentation was 48.64% with the combined strategy versus 33.26% with phototherapy alone. Early type III subgroup comparisons were not significant. The result addresses addition to supervised phototherapy in that selected disease population; general cosmetic tanning was outside the trial's question. Original vitiligo trial.
Safety and tolerability
The controlled EPP trials reported mainly mild or moderate events, including nausea, headache and local pigment changes. Serious events in those trials were judged unrelated by the investigators. In the German registry, 174 of 200 patients had an event during treatment, 108 had an event judged treatment-related, and four had a serious event judged related. These categories differ: an event occurring during follow-up does not automatically establish drug causation. Pivotal trials; registry Table 2.
Current labeling warns about serious hypersensitivity, including anaphylaxis, and darkening of existing moles or freckles. Severe hypersensitivity to the drug or implant ingredients is a contraindication, and skin monitoring remains part of approved care. The approval applies to the clinical implant and adult EPP indication. Scenesse prescribing information.
What the research means
Afamelanotide's strongest evidence connects a defined implant to a practical problem in EPP: spending more time in light without pain. Differences between the diary endpoints, reaction counts and quality-of-life instruments add useful detail to that conclusion. Registries extend the observation into routine specialist treatment, with selection and variable follow-up shaping what their long-term estimates can show.
The vitiligo trial demonstrates that the same pigment pathway can be investigated for a different clinical goal through combination therapy. Neither that result nor the historical tanning studies establishes a broad cosmetic-use benefit-risk profile. Identity, formulation and the reason for treatment remain central to interpreting the evidence.
FAQs
What is afamelanotide approved for in the US?
Scenesse is indicated to increase pain-free light exposure in adults with a history of EPP phototoxic reactions. This disease-specific indication belongs to the prescription implant. Current label.
Why are the US and European sunlight totals so different?
The trials recorded different daylight windows and definitions over different follow-up periods. Each placebo comparison is informative within its trial; the raw hour totals do not support a direct regional comparison. Pivotal report.
Does the implant correct the underlying EPP defect?
Its pigment response improves light tolerance. The inherited heme-synthesis problem and accumulated photosensitive material remain part of the disease, which is why clinical monitoring and light protection continue.
What did the vitiligo study test?
It tested adding an afamelanotide implant to narrowband UV-B phototherapy in selected adults. The comparator was phototherapy alone, so the result belongs to that combination strategy. Lim and colleagues.
Can the 15-hour apparent half-life describe every melanotan-I preparation?
It comes from a single Scenesse implant study and includes the delivery system’s continuing release. Soluble research formulations and other routes need their own exposure measurements.
Comparisons and related reading
Melanotan II is a different cyclic melanocortin with an early experimental and unregulated-product record. Bremelanotide illustrates a related receptor family developed for a separate clinical indication. The pharmacokinetics explainer helps distinguish depot release, circulating exposure and a later tissue response.
References
- Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neumann NJ, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. Afamelanotide for Erythropoietic Protoporphyria. The New England journal of medicine. 2015;373(1):48–59. DOI: 10.1056/NEJMoa1411481. · Full text (PMC)
Participants given afamelanotide recorded more pain-free sunlight exposure in both trials. The European trial also found fewer phototoxic reactions; the US reaction-count comparison did not establish a difference.
- Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. The British journal of dermatology. 2015;172(6):1601–1612. DOI: 10.1111/bjd.13598. · onlinelibrary.wiley.com
Patients reported better quality of life over prolonged treatment experience.
- Homey B, Schelonke K, Schlegel CM, Bruch-Gerharz D, Weller K, Kiefer L, Stölzel U, Staubach-Renz P, Wegner J, Keller-Melchior R, Walker G, Bochno M, Bilbao P. German Cohort Observational Study to Investigate the Short- and Long-Term Safety and Clinical Effectiveness of Afamelanotide 16 mg (SCENESSE) in Patients With Erythropoietic Protoporphyria (EPP). Photodermatology, photoimmunology & photomedicine. 2025;41(2):e13012. DOI: 10.1111/phpp.13012. · Full text (PMC)
The registry adds experience beyond short trials, with varying follow-up and paired samples.
- Lim HW, Grimes PE, Agbai O, Hamzavi I, Henderson M, Haddican M, Linkner RV, Lebwohl M. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA dermatology. 2015;151(1):42–50. DOI: 10.1001/jamadermatol.2014.1875. · PubMed record
The combined strategy improved average repigmentation, with population and subgroup limits.
The same peptide had different measured exposure across tested formulations.
Defines the approved adult EPP indication, acetate sequence/form, implant pharmacokinetics and current hypersensitivity and skin-monitoring warnings.
Glossary
- EPP
- Erythropoietic protoporphyria, an inherited heme-pathway disorder causing severe light-triggered pain.
- Protoporphyrin
- A heme-pathway intermediate that can trigger tissue reactions when light activates accumulated material.
- Eumelanin
- A dark pigment produced by melanocytes that contributes to protection from light.
- Phototoxicity
- Tissue injury or pain produced when light activates a photosensitive substance.
- Narrowband UV-B
- A supervised phototherapy using a restricted band of ultraviolet-B wavelengths.
- Apparent half-life
- A half-life estimated from the observed concentration decline, which can include the influence of continuing drug input from a delivery system.